CONTEXT: Visceral adipose tissue (VAT) is a key contributor to chronic inflammation in obesity. The 12/15-lipoxygenase pathway (ALOX) is present in adipose tissue (AT) and leads to inflammatory cascades that are causal for the onset of insulin resistance in rodent models of obesity. OBJECTIVE: The pathophysiology of the ALOX 12/15 pathway in human AT is unknown. We characterized the ALOX pathway in different AT depots in obese humans with or without type 2 diabetes (T2D). DESIGN: This study includes a cross-sectional cohort of 46 morbidly obese (body mass index >39 kg/m(2)) nondiabetic (n = 25) and T2D (n = 21) subjects. SETTING: This study was conducted at Eastern Virginia Medical School (Norfolk, Virginia) in collaboration with Sentara Metabolic and Weight Loss Surgery Center (Sentara Medical Group, Norfolk, Virginia). PATIENTS: Twenty-five obese (body mass index 44.8 ± 4.4 kg/m(2)) nondiabetic (hemoglobin A1c 5.83% ± 0.27%) and 21 obese (43.4 ± 4.1 kg/m(2)) and T2D (hemoglobin A1c 7.66% ± 1.22%) subjects were included in the study. The subjects were age matched and both groups had a bias toward female gender. MAIN OUTCOMES AND MEASURES: Expression of ALOX isoforms along with fatty acid substrates and downstream lipid metabolites were measured. Correlations with depot-specific inflammatory markers were also established. RESULTS: ALOX 12 expression and its metabolite 12(S)-hydroxyeicosatetraenoic acid were significantly increased in the VAT of T2D subjects. ALOX 15A was exclusively expressed in VAT in both groups. ALOX 12 expression positively correlated with expression of inflammatory genes IL-6, IL-12a, CXCL10, and lipocalin-2. CONCLUSIONS: ALOX 12 may have a critical role in regulation of inflammation in VAT in obesity and T2D. Selective ALOX 12 inhibitors may constitute a new approach to limit AT inflammation in human obesity.
CONTEXT: Visceral adipose tissue (VAT) is a key contributor to chronic inflammation in obesity. The 12/15-lipoxygenase pathway (ALOX) is present in adipose tissue (AT) and leads to inflammatory cascades that are causal for the onset of insulin resistance in rodent models of obesity. OBJECTIVE: The pathophysiology of the ALOX 12/15 pathway in human AT is unknown. We characterized the ALOX pathway in different AT depots in obesehumans with or without type 2 diabetes (T2D). DESIGN: This study includes a cross-sectional cohort of 46 morbidly obese (body mass index >39 kg/m(2)) nondiabetic (n = 25) and T2D (n = 21) subjects. SETTING: This study was conducted at Eastern Virginia Medical School (Norfolk, Virginia) in collaboration with Sentara Metabolic and Weight Loss Surgery Center (Sentara Medical Group, Norfolk, Virginia). PATIENTS: Twenty-five obese (body mass index 44.8 ± 4.4 kg/m(2)) nondiabetic (hemoglobin A1c 5.83% ± 0.27%) and 21 obese (43.4 ± 4.1 kg/m(2)) and T2D (hemoglobin A1c 7.66% ± 1.22%) subjects were included in the study. The subjects were age matched and both groups had a bias toward female gender. MAIN OUTCOMES AND MEASURES: Expression of ALOX isoforms along with fatty acid substrates and downstream lipid metabolites were measured. Correlations with depot-specific inflammatory markers were also established. RESULTS:ALOX 12 expression and its metabolite 12(S)-hydroxyeicosatetraenoic acid were significantly increased in the VAT of T2D subjects. ALOX 15A was exclusively expressed in VAT in both groups. ALOX 12 expression positively correlated with expression of inflammatory genes IL-6, IL-12a, CXCL10, and lipocalin-2. CONCLUSIONS:ALOX 12 may have a critical role in regulation of inflammation in VAT in obesity and T2D. Selective ALOX 12 inhibitors may constitute a new approach to limit AT inflammation in humanobesity.
Authors: Jennifer Rivera; Natalie Ward; Jonathan Hodgson; Ian B Puddey; John R Falck; Kevin D Croft Journal: Clin Chem Date: 2004-01 Impact factor: 8.327
Authors: Anca D Dobrian; David C Lieb; Qian Ma; John W Lindsay; Banumathi K Cole; Kaiwen Ma; Swarup K Chakrabarti; Norine S Kuhn; Stephen D Wohlgemuth; Mark Fontana; Jerry L Nadler Journal: Biochem Biophys Res Commun Date: 2010-11-19 Impact factor: 3.575
Authors: Netra Joshi; Eric K Hoobler; Steven Perry; Giovanni Diaz; Brian Fox; Theodore R Holman Journal: Biochemistry Date: 2013-10-30 Impact factor: 3.162
Authors: Yu Wang; Karen S L Lam; Edward W Kraegen; Gary Sweeney; Jialiang Zhang; Annette W K Tso; Wing-Sun Chow; Nelson M S Wat; Jian Yu Xu; Ruby L C Hoo; Aimin Xu Journal: Clin Chem Date: 2006-10-13 Impact factor: 8.327
Authors: Cosima Arnold; Marija Markovic; Katrin Blossey; Gerd Wallukat; Robert Fischer; Ralf Dechend; Anne Konkel; Clemens von Schacky; Friedrich C Luft; Dominik N Muller; Michael Rothe; Wolf-Hagen Schunck Journal: J Biol Chem Date: 2010-08-23 Impact factor: 5.157
Authors: Stuart P Weisberg; Daniel McCann; Manisha Desai; Michael Rosenbaum; Rudolph L Leibel; Anthony W Ferrante Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Benjamin P Fairfax; Fredrik O Vannberg; Jayachandran Radhakrishnan; Hakon Hakonarson; Brendan J Keating; Adrian V S Hill; Julian C Knight Journal: Hum Mol Genet Date: 2009-11-26 Impact factor: 6.150
Authors: Banumathi K Cole; Margaret A Morris; Wojciech J Grzesik; Kendall A Leone; Jerry L Nadler Journal: Mediators Inflamm Date: 2012-12-27 Impact factor: 4.711
Authors: Yumi Imai; Anca D Dobrian; Margaret A Morris; David A Taylor-Fishwick; Jerry L Nadler Journal: Diabetologia Date: 2016-02-11 Impact factor: 10.122
Authors: Sarah A Tersey; Esther Bolanis; Theodore R Holman; David J Maloney; Jerry L Nadler; Raghavendra G Mirmira Journal: Mol Endocrinol Date: 2015-03-24
Authors: Niharika Samala; Sarah A Tersey; Naga Chalasani; Ryan M Anderson; Raghavendra G Mirmira Journal: J Diabetes Complications Date: 2017-07-31 Impact factor: 2.852